Caribou Biosciences (CRBU) EBITDA Margin (2020 - 2026)
Caribou Biosciences (CRBU) reported EBITDA Margin of 1051.77% for Q1 2026, up 65154.0% year-over-year from N/an in Q1 2025, and down 56.55% quarter-over-quarter from 671.86% in Q4 2025.
Caribou Biosciences (CRBU) EBITDA Margin (2020 - 2026) Analysis & Trends
Caribou Biosciences (CRBU) has 7 years of EBITDA Margin data on file, last reported at 1051.77% in Q1 2026.
- EBITDA Margin for Q1 2026 came in at 1051.77%, up 65154.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 1190.83% (up 29508.0% YoY), and the FY2025 annual result was 1328.77%, up 16093.0% from the prior year.
- EBITDA Margin eased to 1051.77% in Q1 2026 per CRBU's latest filing, from 671.86% in the prior quarter.
- Over five years, EBITDA Margin peaked at 41.62% in Q3 2023 and troughed at 2033.18% in Q2 2025.
- A 5-year average of 1082.43% and a median of 941.37% in 2023 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2024 and 2025: EBITDA Margin tumbled 161728 bps in 2024, then soared 106256 bps in 2025.
- A 5-year view of EBITDA Margin shows it stood at 717.01% in 2022, then slumped by 31 bps to 941.37% in 2023, then tumbled by 84 bps to 1734.42% in 2024, then soared by 61 bps to 671.86% in 2025, then sank by 57 bps to 1051.77% in 2026.
- Business Quant data shows CRBU's EBITDA Margin at 1051.77% in Q1 2026, 671.86% in Q4 2025, and 1250.91% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Caribou Biosciences | 156.73 Mn | 39.11 Mn | - | -1,051.77% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,051.77% |
| Dec 31, 2025 | -671.86% |
| Sep 30, 2025 | -1,250.91% |
| Jun 30, 2025 | -2,033.18% |
| Mar 31, 2025 | -1,703.31% |
| Dec 31, 2024 | -1,734.42% |
| Sep 30, 2024 | -1,658.89% |
| Jun 30, 2024 | -1,088.16% |
| Mar 31, 2024 | -1,712.06% |
| Dec 31, 2023 | -941.37% |
| Sep 30, 2023 | -41.62% |
| Jun 30, 2023 | -796.94% |
| Mar 31, 2023 | -778.30% |
| Dec 31, 2022 | -717.01% |
| Sep 30, 2022 | -820.50% |
| Jun 30, 2022 | -648.59% |
| Mar 31, 2022 | -752.33% |
| Dec 31, 2021 | -727.39% |
| Sep 30, 2021 | -527.38% |
| Jun 30, 2021 | -969.58% |